Evaluation of GeranylGeranylAcetone in Heart Failure With Preserved Ejection Fraction

Summary

The goal of this double-blind randomized, placebo-controlled cross-over trial is to evaluate the effectiveness of GerenylGeranylAcetone (GGA) in patients with Heart Failure with a preserved ejection fraction. The main questions it aims to answer are: * What is the effect of GGA on diastolic function? * What is the effect of GGA on endothelial function? Main study tasks: * Participants will be treated with either GGA or placebo for 13 weeks. After this they will have a break (wash-out) period for 6 weeks and then cross over to the other study arm. * Cardiac function will be measured using echocardiogram in all participants * Renal measurements and endothelial measurements will be performed on the participants. * Participants will perform a 5 minute walking distance test for functional capacity. * Participants will fill out questionnaires to score signs \& symptoms. Researchers will compare the patients to themselves to see if the drug improves diastolic- and endothelial function.

Timeline

Start

2023-04-26

Primary completion

2024-08-30

Completion

2024-08-30

Drugs

Indications